tradingkey.logo

Grail falls after Q1 revenue miss

ReutersMay 14, 2025 1:50 PM

Shares of cancer diagnostic maker Grail GRAL.O down 14.5% at $36.66

Company late on Tuesday reported Q1 revenue of $31.8 million, missing analysts' average expectation of $35.2 million - data compiled by LSEG

GRAL reported quarterly loss of $3.10/shr vs estimates for loss of $4.09/shr

"We think the company will benefit from upcoming catalysts and its 'trailblazer' advantage in multi-cancer early detection (MCED)," brokerage Canaccord Genuity says

Galleri is a blood test designed to detect more than 50 types of cancer and it is currently sold only in the U.S.

GRAL continues to expect to generate U.S. Galleri y-o-y revenue growth of 20% to 30% in 2025

Brokerage raises long-term Galleri revenue estimates and says "we believe the shares do not reflect the company's growth potential, as we see it"

Including session's moves, stock up 140.3% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI